Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Endocyte Inc (ECYT) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Endocyte Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1235007.
Total stock buying since 2014: $111,004.
Total stock sales since 2014: $2,874,072.
Total stock option exercises since 2014: $3,693,190.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2018 | 0 | $0 | 133,520 | $2,151,544 | 503,433 | $2,600,353 |
| 2017 | 5,600 | $27,104 | 73,742 | $339,911 | 135,908 | $373,363 |
| 2016 | 30,000 | $83,900 | 23,244 | $59,272 | 52,355 | $107,954 |
| 2015 | 0 | $0 | 29,883 | $172,992 | 119,078 | $465,811 |
| 2014 | 0 | $0 | 21,479 | $150,353 | 55,466 | $145,709 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2018-12 | 0 | $0 | 0 | $0 | 480,614 | $2,539,559 |
| 2018-10 | 0 | $0 | 88,438 | $1,375,877 | 0 | $0 |
| 2018-08 | 0 | $0 | 26,957 | $532,937 | 17,366 | $44,108 |
| 2018-06 | 0 | $0 | 13,089 | $197,054 | 0 | $0 |
| 2018-03 | 0 | $0 | 5,036 | $45,676 | 0 | $0 |
| 2018-02 | 0 | $0 | 0 | $0 | 5,453 | $16,686 |
| 2017-12 | 0 | $0 | 73,742 | $339,911 | 91,623 | $280,365 |
| 2017-11 | 5,600 | $27,104 | 0 | $0 | 0 | $0 |
| 2017-05 | 0 | $0 | 0 | $0 | 44,285 | $92,998 |
| 2016-12 | 0 | $0 | 23,244 | $59,272 | 26,178 | $54,973 |
| 2016-11 | 0 | $0 | 0 | $0 | 15,706 | $32,982 |
| 2016-07 | 0 | $0 | 0 | $0 | 10,471 | $19,999 |
| 2016-01 | 30,000 | $83,900 | 0 | $0 | 0 | $0 |
| 2015-12 | 0 | $0 | 0 | $0 | 13,089 | $24,999 |
| 2015-03 | 0 | $0 | 29,883 | $172,992 | 40,000 | $142,000 |
| 2015-02 | 0 | $0 | 0 | $0 | 65,989 | $298,812 |
| 2014-11 | 0 | $0 | 0 | $0 | 19,060 | $36,404 |
| 2014-10 | 0 | $0 | 0 | $0 | 14,927 | $38,317 |
| 2014-08 | 0 | $0 | 21,479 | $150,353 | 21,479 | $70,988 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-12-17 | Andriole Michael T. (Chief Financial Officer) | Option Ex | 25,000 | 2.22 | 55,500 |
| 2018-12-17 | Armour Alison A. (Chief Medical Officer) | Option Ex | 49,213 | 3.50 | 172,245 |
| 2018-12-17 | Taylor Beth (VP Finance & Chief Acctg Offcr) | Option Ex | 48,854 | 4.51 | 220,331 |
| 2018-12-17 | Low Philip S (Chief Science Officer) | Option Ex | 140,214 | 6.67 | 934,946 |
| 2018-12-17 | Sherman Michael A. (President and CEO) | Option Ex | 115,559 | 5.64 | 651,637 |
| 2018-12-17 | Leamon Christopher P (Vice President of Research) | Option Ex | 101,774 | 4.96 | 504,900 |
| 2018-10-09 | Andriole Michael T. (Chief Financial Officer) | Sale | 635 | 15.85 | 10,064 |
| 2018-10-05 | Chelius Erik C. (Vice President CMC) | Sale | 4,514 | 15.56 | 70,242 |
| 2018-10-05 | Andriole Michael T. (Chief Financial Officer) | Sale | 17,283 | 15.55 | 268,785 |
| 2018-10-05 | Armour Alison A. (Chief Medical Officer) | Sale | 9,111 | 15.56 | 141,748 |
| 2018-10-05 | Parker Katherine (VP of Human Resources) | Sale | 6,771 | 15.55 | 105,316 |
| 2018-10-05 | Taylor Beth (VP Finance & Chief Acctg Offcr) | Sale | 7,022 | 15.56 | 109,290 |
| 2018-10-05 | Low Philip S (Chief Science Officer) | Sale | 5,928 | 15.56 | 92,239 |
| 2018-10-05 | Sherman Michael A. (President and CEO) | Sale | 28,146 | 15.55 | 437,754 |
| 2018-10-05 | Leamon Christopher P (Vice President of Research) | Sale | 9,028 | 15.56 | 140,439 |
| 2018-08-29 | Leamon Christopher P (Vice President of Research) | Sale | 4,696 | 20.00 | 93,920 |
| 2018-08-29 | Leamon Christopher P (Vice President of Research) | Option Ex | 4,696 | 2.54 | 11,927 |
| 2018-08-28 | Taylor Beth (VP Finance & Chief Acctg Offcr) | Sale | 7,892 | 20.00 | 157,840 |
| 2018-08-28 | Leamon Christopher P (Vice President of Research) | Sale | 12,670 | 20.00 | 253,400 |
| 2018-08-28 | Leamon Christopher P (Vice President of Research) | Option Ex | 12,670 | 2.54 | 32,181 |
| 2018-08-20 | Taylor Beth (VP Finance & Chief Acctg Offcr) | Sale | 285 | 18.20 | 5,187 |
| 2018-08-01 | Armour Alison A. (Chief Medical Officer) | Sale | 1,414 | 15.98 | 22,590 |
| 2018-06-12 | Leamon Christopher P (Vice President of Research) | Sale | 13,089 | 15.05 | 197,054 |
| 2018-03-09 | Leamon Christopher P (Vice President of Research) | Sale | 5,036 | 9.07 | 45,676 |
| 2018-02-02 | Sherman Michael A. (President and CEO) | Option Ex | 5,453 | 3.06 | 16,686 |
| 2017-12-28 | Low Philip S (Chief Science Officer) | Sale | 50,511 | 4.41 | 222,804 |
| 2017-12-28 | Low Philip S (Chief Science Officer) | Option Ex | 65,445 | 3.06 | 200,261 |
| 2017-12-01 | Leamon Christopher P (Vice President of Research) | Sale | 23,231 | 5.04 | 117,107 |
| 2017-12-01 | Leamon Christopher P (Vice President of Research) | Option Ex | 26,178 | 3.06 | 80,104 |
| 2017-11-13 | Low Philip S (Chief Science Officer) | Buy | 5,600 | 4.84 | 27,104 |
| 2017-05-31 | Sherman Michael A. (President, CEO and CFO) | Option Ex | 44,285 | 2.10 | 92,998 |
| 2016-12-30 | Leamon Christopher P (Vice President of Research) | Sale | 23,244 | 2.55 | 59,272 |
| 2016-12-30 | Leamon Christopher P (Vice President of Research) | Option Ex | 26,178 | 2.10 | 54,973 |
| 2016-11-15 | Low Philip S (Chief Science Officer) | Option Ex | 15,706 | 2.10 | 32,982 |
| 2016-07-27 | Brauer Keith E | Option Ex | 10,471 | 1.91 | 19,999 |
| 2016-01-19 | Middleton Fred A | Buy | 10,000 | 2.79 | 27,900 |
| 2016-01-15 | Middleton Fred A | Buy | 20,000 | 2.80 | 56,000 |
| 2015-12-24 | Low Philip S (Chief Science Officer) | Option Ex | 13,089 | 1.91 | 24,999 |
| 2015-03-03 | Nguyen Binh (VP of Medical Affairs) | Sale | 29,883 | 5.79 | 172,992 |
| 2015-03-03 | Nguyen Binh (VP of Medical Affairs) | Option Ex | 40,000 | 3.55 | 142,000 |
| 2015-02-10 | Low Philip S (Chief Science Officer) | Option Ex | 544 | 1.91 | 1,039 |
| 2015-02-10 | Leamon Christopher P (Vice President of Research) | Option Ex | 13,089 | 1.91 | 24,999 |
| 2015-02-06 | Ellis P Ron (President and CEO) | Option Ex | 52,356 | 5.21 | 272,774 |
| 2014-11-05 | Ellis P Ron (President and CEO) | Option Ex | 19,060 | 1.91 | 36,404 |
| 2014-10-31 | Sherman Michael A. (COO and CFO) | Option Ex | 14,927 | 2.57 | 38,317 |
| 2014-08-11 | Lovejoy Chandra D (VP of Regulatory Affairs) | Sale | 21,479 | 7.00 | 150,353 |
| 2014-08-11 | Lovejoy Chandra D (VP of Regulatory Affairs) | Option Ex | 21,479 | 3.31 | 70,988 |
Insider trading activities including stock purchases, stock sales, and option exercises of ECYT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Endocyte Inc (symbol ECYT, CIK number 1235007) see the Securities and Exchange Commission (SEC) website.